SERAC1

Across TCGA pan-cancer cohorts, SERAC1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SERAC1 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SERAC1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SERAC1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SERAC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.863	0.448	.007	18	view →
LUAD	DFS	Median	All	0.764	0.495	.003	12	view →
CCRCC	DFS	Tertile	IV	0.961	0.207	.024	11	view →
GBM	DFS	Quartile	All	0.955	0.661	.004	4	view →
LSCC	OS	Tertile	All	1.000	0.848	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SERAC1–PDAC (DFS)

Open the PDAC breakdown →